$ELUT

ELUTIA INC. (ELUT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

ELUTIA INC. (ELUT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. ELUTIA INC._June 11, 2026 0001708527 false 0001708527 2026-06-11 2026-06-11 ​ ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ ​ FORM 8-K ​ ​ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of

Original reporting
Published Jun 16, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$ELUT
Neutral
medium confidence
Mentioned
$ELUT
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ELUTNeutralLow
01

Why it matters

The newly approved plan terms expand the available share pool and extend the plan’s operating window, which can influence dilution expectations and future compensation expense timing.

02

Market read

This is primarily corporate-governance/compensation-plan news; it may slightly shift dilution sentiment but lacks operating or financial guidance changes.

03

What to watch

Traders may overreact to the share-count increase without considering the company’s actual burn rate and historical equity award usage, which are not provided here.

Relevance 6/10Novelty 4/10Timing: post-annual meeting (filed June 16, 2026; meeting June 11, 2026)

Background

The 8-K reports results of Elutia’s June 11, 2026 annual meeting and the approval of a First Amendment to its Amended and Restated 2020 Incentive Award Plan.

Company-level read

Ticker impact

$ELUTNeutralMedium confidence
Context

Elutia’s stockholders approved an amendment to its 2020 Incentive Award Plan, increasing share authorization by 3,000,000 and extending the plan through 2036.

Expected impact

Likely limited near-term impact; any reaction would be small and sentiment-driven around dilution/compensation optics.

Evidence & confidence

The filing is an 8-K describing shareholder approval of equity-plan terms (share pool and plan duration) rather than earnings, guidance, or a transaction.

Market effects

Routine equity-plan governance updates; limited read-across to the broader small-cap biotech/healthcare services space.

None.

None.

Counterpoint

The plan amendment could be viewed as a positive governance/retention signal (more flexibility for equity awards) rather than dilution risk.

Key entities

  • Elutia Inc.

    Nasdaq-listed issuer (ELUT) that received shareholder approval for an incentive plan amendment and other annual-meeting proposals.

  • PricewaterhouseCoopers LLP

    Ratified as independent registered public accounting firm for the year ending Dec. 31, 2026.

Related articles

$ELUTMed

ELUTIA INC. (ELUT): Results of Operations and Financial Condition

ELUTIA INC. (ELUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 elut-20260813xex99d1.htm EX-99.1 Exhibit 99.1 ​ Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results ​ Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track ​ ● F

$ELUTMedAI 8/10

96% of Plastic Surgeons Interested in Elutia’s NXT-41x

Elutia (Nasdaq: ELUT) reported Q2 2026 results and said it secured up to $26 million in non-equity funding for its NXT-41x program, including a $15 million credit facility and up to $11 million from a SimpliDerm divestiture. Q2 net sales were $2.4M, with a $7.6M net loss. The company cites a 96% surgeon interest survey and expects FDA decisions for NXT-41 in 4Q 2026 and NXT-41x in 1H 2027.